NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 3 October 2024

**Location:** Manchester NICE Office/Zoom (hybrid)

## Attendees

Committee members present

1. Dr Megan John (Chair - Topic 1, Vice-chair - Topic 2) Present for all items
2. Dr Raju Reddy (Vice-chair - Topic 1, Chair - Topic 2) Present for all items
3. Professor Amanda Adler (Observing) Present for all items
4. Martin Bradley Present for all items
5. Paul Caulfield Present for all items
6. Craig Cook Present for all items
7. Professor Sofia Dias Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Items 1.1 to 4.2.2
10. Sue Wen Leo Items 1.1 to 4.2.2
11. Dr Guy Makin Present for all items
12. Dr Philip Mallender Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Carole Pitkeathley Present for all items
16. Dr Ben Searle Present for all items
17. Sophia Steer Present for all items
18. Dr Will Sullivan Present for all items
19. Dr Savvas Vlachos Present for all items
20. Dr Salman Waqar (Observing) Present for all items
21. Dr Zenas Yiu Present for all items

NICE staff (key players) present

Ian Watson, Associate Director Present for all items

Leena Issa, Project Manager Items 1.1 to 4.2.2

Albany Chandler, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

George Millington, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Celia Mayers, Project Manager Items 5.1 to 5.2.2

Samuel Slayen, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Lauren Elston, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Elsa Marquez, Bristol Technology Assessment Group Items 1.1 to 4.1.3

Nicky Welton, Bristol Technology Assessment Group Items 1.1 to 4.1.3

Isaac MacKenzie, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Melina Vasileiou, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Shobhit Baijal, Consultant Medical Oncologist, Clinical expert, nominated by British Thoracic Oncology Group Items 1.1 to 4.1.3

xxxxxxxxxxx, Patient expert, nominated by NICE Items 1.1 to 4.1.3

Professor Peter Clark, CDF Clinical lead, NHS England Items 1.1 to 5.2.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Andrew Fox.

### News and announcements

* 1. The Chair welcomed new committee member Dr Salman Waqar and returning committee member Professor Amanda Adler who will be supporting TAC D over the next few months.

### Minutes from the last meeting

* 1. The August 2024 and September 2024 committee minutes were not available for approval. It was agreed that they would be approved at the November 2024 committee meeting.

### Appraisal of osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11408/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Sofia Dias, Craig Cook and Paul Caulfield.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11408>

### Appraisal of pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

* 1. Part 1 – Open session
		1. The Chair, Dr Raju Reddy, welcomed the invited expert, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme (MSD).
		2. The Chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10784/documents).
		3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Dr Raju Reddy.
	2. Part 2 - Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10784>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 6 November 2024 and will start promptly at 9.00am.